Peptide Lab HQ Research Guide
Dihexa
A research-focused compound profile covering Dihexa identity, angiotensin IV analog research, HGF/c-Met pathway context, neurotrophic signaling models, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Dihexa |
|---|---|
| Common Research Names | PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide |
| Compound Type | Angiotensin IV-derived oligopeptide / modified peptidomimetic research compound |
| CAS Number | 1401708-83-5 |
| PubChem CID | 129010512 |
| UNII | 9WYX65A5C2 |
| Core Research Structure | Hexanoyl-Tyr-Ile-Ahx-NH₂ |
| Full Name | N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide |
| Molecular Formula | C₂₇H₄₄N₄O₅ |
| Molecular Weight | Approximately 504.66 g/mol |
| Research Category | Angiotensin IV analog, HGF/c-Met pathway context, neurotrophic signaling, synaptogenesis, cognitive-function, neuroplasticity, and CNS research |
| Research Context | Commonly discussed in preclinical research involving HGF/c-Met signaling context, dendritic spine formation, synaptic connectivity, cognitive-function models, and neurodegenerative disease model research. |
| Evidence Caveat | Several foundational Dihexa mechanism claims should be interpreted cautiously because a key 2014 HGF/c-Met mechanistic paper was retracted in 2025. |
| Appearance | White to off-white lyophilized powder or solid, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
5-Amino-1MQ is commonly studied in controlled research models involving nicotinamide N-methyltransferase activity, metabolic pathway regulation, adipose tissue signaling, and cellular energy-balance pathways.
NNMT Pathway Research
5-Amino-1MQ is frequently referenced in research involving nicotinamide N-methyltransferase, an enzyme associated with nicotinamide metabolism and cellular energy regulation.
Metabolic Pathway Models
Used in laboratory models exploring how NNMT-related pathways may influence metabolic signaling, substrate utilization, and cellular energy-balance mechanisms.
Adipose Tissue Studies
Studied in preclinical models involving adipose tissue behavior, fat-cell signaling, and metabolic-response documentation under controlled research conditions.
Nicotinamide / NAD+ Research
Relevant to research exploring nicotinamide availability, NAD+-associated biochemical pathways, and cellular metabolic regulation.
Diet-Induced Obesity Models
Appears in preclinical research models involving diet-induced obesity, metabolic adaptation, and controlled study comparisons using animal research designs.
Microbiome & Metabolome Research
Used in research settings where investigators examine links between metabolic changes, adipose tissue metabolites, and microbiome-related observations.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, study design, compound form, purity, concentration, route of administration in preclinical models, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 10 mg Dihexa |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 5 mg/mL, 1 unit equals 0.05 mg / 50 mcg Dihexa. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Dihexa / PNB-0408 / Angiotensin IV-derived oligopeptide | Dihexa is commonly discussed as an angiotensin IV-derived oligopeptide research compound associated with HGF / c-Met signaling and synaptogenesis research contexts. |
| Preclinical Cognitive Research | Rodent oral reference up to 2 mg/kg/day; i.v. up to 10 mg/kg; i.p. up to 20 mg/kg | Published research summaries report Dihexa in rodent cognitive-dysfunction models, but these animal-study amounts are not directly convertible into a research-chemical vial protocol. |
| Cell-Culture / Synaptogenesis Research | Model-dependent nanomolar exposure | Dihexa has been discussed in neuronal culture and synaptogenesis research involving dendritic spine formation, HGF potentiation, c-Met signaling, and neuroplasticity pathway documentation. |
| Public Protocol-Style Reference | 5–20 mg once daily oral reference over 4–6 weeks | Public protocol-style references describe Dihexa as commonly oral or sublingual, not as a validated injectable vial protocol. These are not clinical dosing standards. |
| Half-Life / Accumulation Context | Long half-life reported in rodent research | Research summaries report a long Dihexa half-life in rodents, which is important when interpreting repeated-exposure or accumulation-style research models. |
| Safety / Mechanism Concern | HGF / c-Met pathway activation context | Research summaries note theoretical concerns involving sustained HGF / c-Met signaling and limited long-term safety data. This should be framed as research-context information only. |
| Clinical / Research-Chemical Status | No established human dosing protocol | No published human clinical studies establish a universal Dihexa protocol. Public protocol-style references should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 5 mg/mL | U-100 Unit Reference | Approx. References per 10 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.10 mL | 10 units | 20 |
| 1 mg / 1000 mcg | 0.20 mL | 20 units | 10 |
| 2 mg / 2000 mcg | 0.40 mL | 40 units | 5 |
| 2.5 mg / 2500 mcg | 0.50 mL | 50 units | 4 |
| 5 mg / 5000 mcg | 1.00 mL | 100 units | 2 |
| 7.5 mg / 7500 mcg | 1.50 mL | 150 units | 1.3 |
| 10 mg / 10000 mcg | 2.00 mL | 200 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Weeks 1–2 | Initial once daily public protocol-style reference | 5 mg | 100 units / 1.00 mL |
| Weeks 3–4 | Once daily public protocol-style reference | 7.5 mg | 150 units / 1.50 mL |
| Weeks 5–6 | Upper single-vial reference | 10 mg | 200 units / 2.00 mL |
| Standard Public Reference Range | Once daily oral protocol-style context | 10–15 mg | 10 mg = 200 units / 2.00 mL; 15 mg exceeds one 10 mg vial |
| Advanced Public Reference Range | Once daily oral protocol-style context | 15–20 mg | Exceeds one 10 mg vial; included as public oral-reference context only |
| Weeks 7+ | Optional extended research window | Model-dependent | Not established for reconstituted research-vial format |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture Observation Window | 30 minutes to several days | Used for synaptogenesis, dendritic-spine, HGF / c-Met, neuronal survival, inflammatory-marker, or cellular pathway documentation depending on the model. |
| Rodent Cognitive Research Window | Study-specific | Published preclinical research has used Dihexa in rodent cognition, learning, memory, and neuroplasticity models with route- and model-dependent exposure windows. |
| Public Protocol-Style Initial Window | 2–4 weeks | Public protocol-style references describe an initial assessment window using lower oral reference amounts; this is not a validated reconstituted vial protocol. |
| Public Protocol-Style Cycle Window | 4–6 weeks | Public protocol-style references commonly describe short cycle windows because of Dihexa’s long half-life and limited human safety data. |
| Extended Observation Window | 6+ weeks | Longer research windows should be interpreted cautiously due to limited long-term safety data and theoretical HGF / c-Met pathway concerns. |
| Follow-Up / Washout | Several weeks or longer | Used to document post-study observations, marker return, tolerability resolution, cognitive-marker persistence, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Dihexa, also known as PNB-0408, is commonly discussed as an angiotensin IV-derived oligopeptide associated with HGF / c-Met signaling, synaptogenesis, neuroplasticity, and cognitive-function research contexts. The calculations above assume a 10 mg Dihexa vial reconstituted with 2.0 mL bacteriostatic water, creating a 5 mg/mL concentration reference. Public protocol-style references for Dihexa are commonly oral or sublingual and are not validated injectable-use standards or research-chemical vial protocols. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Dihexa is commonly discussed in research involving angiotensin IV analog activity, HGF/c-Met pathway context, synaptogenesis, dendritic spine formation, neuroplasticity, cognitive-function models, spatial learning, neuroinflammation, and PI3K/AKT signaling context.
Evidence Limitations
Dihexa research is primarily preclinical. A key 2014 mechanistic paper was retracted in 2025, so HGF/c-Met mechanism claims should be presented cautiously and clearly separated from independently validated findings.
Safety Considerations
Research discussion should account for HGF/c-Met pathway relevance, unresolved long-term safety, cancer-pathway concerns, CNS pathway activity, compound purity, solvent compatibility, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.